Post Profile






Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

(European Society for Medical Oncology) Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented today at the ESMO 2017 Congress in Madrid.
read more

share

Related Posts


Afatinib shows clinical benefit for lung cancer patients with brain metastases

Academics / General Science : Science Codex

DENVER - Non-small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival (PFS) and response from the EGFR tyrosine kinase inhibitor (TKI...

High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer

Academics / General Science : Science Codex

DENVER – Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-...

Osimertinib given as first-line treatment may alter biology of EGFR mutated NSCLC

Academics / General Science : Science Codex

GENEVA, Switzerland, 14 April 2016 - The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small-cell lung cancer (NSCLC...

Different Approach Suggested After Progression In NSCLC Patients

Health : Medical News Today

Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib or EGFR...

Afatinib shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints

Health : Medical News Today

Data from the LUX-Lung clinical trial programme, investigating afatinib in patients with advanced non-small cell lung cancer (NSCLC), have been published in the Journal of Clinical Oncology. These data include results from the pivot...

Comments


Copyright © 2016 Regator, LLC